561 related articles for article (PubMed ID: 17039261)
1. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
[TBL] [Abstract][Full Text] [Related]
2. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
3. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
[TBL] [Abstract][Full Text] [Related]
4. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
Sfikakis PP; Theodossiadis PG; Katsiari CG; Kaklamanis P; Markomichelakis NN
Lancet; 2001 Jul; 358(9278):295-6. PubMed ID: 11498218
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for the treatment of resistant oral ulcers in Behçet's disease: a case report and review of the literature.
Almoznino G; Ben-Chetrit E
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S99-102. PubMed ID: 17949561
[TBL] [Abstract][Full Text] [Related]
6. Behçet's disease: a new target for anti-tumour necrosis factor treatment.
Sfikakis PP
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii51-3. PubMed ID: 12379622
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of genital ulcers with infliximab in Behcet's disease.
Haugeberg G; Velken M; Johnsen V
Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
[No Abstract] [Full Text] [Related]
8. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment for severe orogenital ulceration in Behçet's disease.
Connolly M; Armstrong JS; Buckley DA
Br J Dermatol; 2005 Nov; 153(5):1073-5. PubMed ID: 16225632
[No Abstract] [Full Text] [Related]
10. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
11. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Barešić M; Reihl M; Habek M; Vukojević N; Anić B
Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
[TBL] [Abstract][Full Text] [Related]
13. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
14. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of a single dose of infliximab in the treatment of Behçet's disease uveitis.
Arayssi T; Hamra R; Homeidan F; Uthman I; Awwad ST; Mroue K; Mansour W; Bashshur ZF
Clin Exp Rheumatol; 2005; 23(3):427. PubMed ID: 15971438
[No Abstract] [Full Text] [Related]
16. An incomplete form of childhood Behçet's disease treated with infliximab.
Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
[TBL] [Abstract][Full Text] [Related]
18. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease.
Triolo G; Vadalà M; Accardo-Palumbo A; Ferrante A; Ciccia F; Giardina E; Citarrella P; Lodato G; Licata G
Ann Rheum Dis; 2002 Jun; 61(6):560-1. PubMed ID: 12006336
[No Abstract] [Full Text] [Related]
20. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
